In Silico and In Vitro Assessment of Coriandrum sativum Extract Potential for Overcoming Cisplatin Resistance in Non Small Cell Lung Cancer

Abstract

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for 85% of cases of lung cancer. NSCLC is commonly treated with cisplatin, however, NSCLC develops resistance to cisplatin via several mechanisms, which reduces treatment efficacy and becomes a major challenge in its treatment. Several plant extracts have been researched as potential anticancer, including Coriandrum sativum, which contains many bioactive compounds such as quercetin and has shown promise in overcoming cisplatin resistance in NSCLC. This research investigates the C.sativum extract potential to overcome cisplatin resistance NSCLC by employing molecular docking, drug-likeness, and cytotoxic activity. The C.sativum bioactive compound interacted with important biomarker proteins involved in cisplatin resistance NSCLC and demonstrated cisplatin resistance overcoming capability. C.sativum enhances chemosensitivity and reduces resistance mechanisms in NSCLC which may improve therapeutic outcomes. Further studies are needed to explore the clinical applicability of these findings.